BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matsushita H, Ikeda F, Iwasaki Y, Seki H, Nanba S, Takeuchi Y, Moritou Y, Yasunaka T, Onishi H, Miyake Y, Takaki A, Nouso K, Yamamoto K. Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C: Health-related quality of life and pegylated interferon-α for hepatitis C virus. J Gastroenterol Hepatol 2014;29:337-43. [DOI: 10.1111/jgh.12337] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Trinks J, Hulaniuk ML, Redal MA, Flichman D. Clinical utility of pharmacogenomics in the management of hepatitis C. Pharmgenomics Pers Med 2014;7:339-47. [PMID: 25382982 DOI: 10.2147/PGPM.S52624] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Xie Q, Xuan JW, Tang H, Ye XG, Xu P, Lee IH, Hu SL. Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China. World J Hepatol 2019; 11(5): 421-441 [PMID: 31183003 DOI: 10.4254/wjh.v11.i5.421] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Souza NP, Villar LM, Garbin AJ, Rovida TA, Garbin CA. Assessment of health-related quality of life and related factors in patients with chronic liver disease. Braz J Infect Dis 2015;19:590-5. [PMID: 26361840 DOI: 10.1016/j.bjid.2015.08.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
4 Younossi ZM, Tanaka A, Eguchi Y, Lim YS, Yu ML, Kawada N, Dan YY, Brooks-Rooney C, Negro F, Mondelli MU. The impact of hepatitis C virus outside the liver: Evidence from Asia. Liver Int. 2017;37:159-172. [PMID: 27748564 DOI: 10.1111/liv.13272] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
5 Liu CY, Ko PH, Yen HR, Cheng CH, Li YH, Liao ZH, Hsu CH. The Chinese medicine Kuan-Sin-Yin improves liver function in patients with chronic hepatitis C: A randomised and placebo-controlled trial. Complement Ther Med 2016;27:114-22. [PMID: 27515885 DOI: 10.1016/j.ctim.2016.06.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Younossi ZM, Stepanova M, Henry L. Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C. Value in Health 2016;19:544-51. [DOI: 10.1016/j.jval.2016.02.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
7 Younossi ZM, Stepanova M, Marcellin P, Afdhal N, Kowdley KV, Zeuzem S, Hunt SL. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. Hepatology 2015;61:1798-808. [PMID: 25627448 DOI: 10.1002/hep.27724] [Cited by in Crossref: 106] [Cited by in F6Publishing: 102] [Article Influence: 15.1] [Reference Citation Analysis]
8 Zhang M, Gu Y, Huang S, Lou Q, Xie Q, Xu Z, Chen Y, Pan F, Xu S, Liu S, Tao J, Liu S, Cai J, Chen P, Qian L, Wang C, Liang C, Huang H, Pan H, Su H, Cheng J, Zhang Y, Hu W, Zou Y. Copy number variations and polymorphisms in HSP90AB1 and risk of systemic lupus erythematosus and efficacy of glucocorticoids. J Cell Mol Med 2019;23:5340-8. [PMID: 31124601 DOI: 10.1111/jcmm.14410] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
9 Li M, Zhuang H, Wei L. How would China achieve WHO's target of eliminating HCV by 2030? Expert Rev Anti Infect Ther 2019;17:763-73. [PMID: 31578079 DOI: 10.1080/14787210.2019.1675509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
10 Whiteley D, Elliott L, Cunningham-burley S, Whittaker A. Health-Related Quality of Life for individuals with hepatitis C: A narrative review. International Journal of Drug Policy 2015;26:936-49. [DOI: 10.1016/j.drugpo.2015.04.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
11 Suenaga R, Suka M, Hirao T, Hidaka I, Sakaida I, Ishida H. Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages. PLoS One 2021;16:e0248748. [PMID: 33793594 DOI: 10.1371/journal.pone.0248748] [Reference Citation Analysis]
12 Boscarino JA, Lu M, Moorman AC, Gordon SC, Rupp LB, Spradling PR, Teshale EH, Schmidt MA, Vijayadeva V, Holmberg SD; Chronic Hepatitis Cohort Study (CHeCS) Investigators. Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: the Chronic Hepatitis Cohort Study (CHeCS). Hepatology 2015;61:802-11. [PMID: 25203533 DOI: 10.1002/hep.27422] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 7.7] [Reference Citation Analysis]
13 Kawakubo M, Eguchi Y, Okada M, Iwane S, Oeda S, Otsuka T, Nakashita S, Araki N, Koga A. Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life. Intern Med 2018;57:1959-66. [PMID: 29526929 DOI: 10.2169/internalmedicine.0091-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
14 Miyasaka A, Yoshida Y, Suzuki A, Takikawa Y. Health-related quality of life in patients with chronic hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response. Qual Life Res 2021. [PMID: 34013404 DOI: 10.1007/s11136-021-02874-6] [Reference Citation Analysis]